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Abstract
Background: Total pancreatectomy (TP) is performed for various indications. Historically, morbidity and
mortality have been high. Recent series reporting improved peri-operative mortality have renewed interest
in TP. We performed a national review of TP including indication, patient/hospital characteristics, com-
plications and peri-operative mortality.
Methods: The Nationwide Inpatient Sample (NIS) was queried to identify TPs performed during 1998 to
2006. Univariate analyses were used to compare patient/hospital characteristics. Multivariable logistic
regression was performed to identify predictors of in-hospital mortality. Post-operative complications/
disposition were assessed.
Results: From 1998 to 2006, 4013 weighted patient-discharges occurred for TP. Fifty-three per cent
were male; mean age 58 years. Indication: neoplastic disease 67.8%. Post-operative complications
occurred in 28%. Univariate analyses: TPs increased significantly (1998, n = 384 vs. 2006 n = 494, P <
0.01). 77.1% of TPs occurred in teaching hospitals (P < 0.0001), 86.4% in hospitals performing <five
pancreatectomies/year (P < 0.0001). In-patient mortality was 8.5% with a significant decrease (12.4%
1998–2000 vs. 5.9% 2002–2006, P < 0.01). Multivariable analyses: advanced age [referent 50 years;
70 Adjusted odds ratio (AOR) 3.4, 95% confidence interval (CI) 1.33–8.67], select patient comorbidities
and year (referent = 2004–2006; 1998–2000 AOR 2.70; 95% CI 1.41–5.14) independently predicted
in-patient mortality whereas hospital surgical volume did not.
Discussion: TP is increasingly performed nationwide with a concomitant decrease in peri-operative
mortality. Patient characteristics, rather than hospital volume, predicted increased mortality.
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Introduction
Total pancreatectomy (TP) was first described by Rockey in 19431
and its popularity increased during the 1960s with the prospect of
improving oncological outcomes and decreasing morbidity from
anastomotic leaks.2 However, subsequent studies demonstrated
TP did not improve Ro resections and had peri-operative mortal-
ity similar to or higher than classic Whipple resections.3,4 Further-
more, TP was complicated by permanent pancreatic endocrine
and exocrine deficiencies.5 This led to surgeons largely abandon-
ing TP and no longer considering TP as a viable option for pan-
creatic disease.
Recently, TP is being revisited as single institution series report
improved per-operative mortality and long-term survival for TP
to be similar to classic Whipple resections.6 Major advances in
the management of the post-operative apancreatic state have
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improved post-operative morbidity associated with TP.7,8 Clinical
indications for TP are increasingly reported in the literature.
Concern regarding the extent of ductal disease for intraductal
papillary mucinous neoplasms (IPMNs) has led some surgeons to
advocate TP for surgical management.9 After TP, intractable pain
associated with chronic pancreatitis refractory to conservative
management has been reported to improve in 80% of patients .10
Multifocal metastatic renal cell carcinoma has been treated with
removal of the entire gland through TP.11
With these recent findings, we sought to perform a current
national review of TP including indications, patient/hospital char-
acteristics, major post-operative complications and in-hospital
mortality.
Methods
Database
The Nationwide Inpatient Sample (NIS) was queried between the
years 1998 to 2006 for patient discharges for TP [International
Classification of Diseases, 9th revision, clinical modification
(ICD-9-CM) procedure code 52.6].12 Patients undergoing TP with
a concurrent diagnosis of traumatic injury during the same hos-
pital stay were excluded from further analyses. The NIS is the
largest national all-payer hospital inpatient care database in the
United States. Data exists for approximately 8 million hospital
discharges per year from a stratified sample of 20% of non-federal
US community hospitals (n = 1045 in 2006) from participating
states (n = 38 in 2006), including academic and specialty hospitals.
The NIS is supported by the Healthcare Cost and Utilization
Project and contains all-payer discharge information for 100% of
patient discharges from participating hospitals. It contains hospi-
tal level information obtained from a direct link to the American
Hospital Association’s annual survey of hospitals, which includes
hospital type (teaching/nonteaching) and geographic region
(Northeast, West, South, Midwest as defined by the US Census
Bureau). A weighting strategy is implemented by the NIS to allow
population-based estimates to be drawn at the national level.
Sampled hospitals are given appropriate weights based on the
number of hospitals they represent in the database for a given
year.13 All statistical analyses were performed based on these
survey weights; therefore, all data provided in the results represent
weighted frequencies.
Patient and hospital characteristics
Patient demographics including age at admission, sex and race
were collected. Race information was excluded frommultivariable
analyses because of the high rate of missing values. Patients were
assigned a Charlson comorbidity score,14 based on ICD-9-CM
diagnoses, according to the methods described by Deyo et al.15 In
addition, independent patient comorbidities were evaluated in
analyses from previously established comorbidity software for use
with national datasets (congestive heart failure, chronic lung
disease, valvular heart disease, renal failure, diabetes mellitus, liver
disease and obesity).16
Indication for TP was determined by primary diagnoses codes
(ICD-9-CM). Indications were categorized as neoplastic disease,
pancreatitis, pancreatic cystic disease and other/unspecified (cat-
egorical ICD-9 codes listed in Appendix 1). Major post-operative
complications were defined by specific diagnoses with codes based
on their validation as true complications rather than comor-
bidities by the methods described by Lawthers et al.17 These were
defined as secondary diagnoses of post-operative infection (except
wound and pneumonia), acute myocardial infarction (MI), aspi-
ration pneumonia, deep venous thrombosis (DVT), pulmonary
embolism (PE), post-operative pulmonary compromise, post-
operative gastrointestinal haemorrhage, reopening of a surgical
site and procedure-related lacerations or perforations. A complete
listing of ICD-9-CM codes used may be found in Appendix 1.
Post-operative length of stay (LOS) was calculated by subtracting
the number of days from admission to the first operation from the
total length of stay.
Annual hospital surgical volume for pancreatectomy utilized
methods described by McPhee et al.18 Low volume hospitals were
defined as performing fewer then five pancreatic resections/year,
and medium/high volume hospitals were defined as performing
five pancreatic resections/year.
Statistical analysis
All data were analysed through the advanced survey procedures
available in SAS version 9.1 (SAS Institute, Cary, NC, USA).
Univariate analyses of categorical variables were performed using
Rao-Scott chi-square tests, with a P-value < 0.05 considered sta-
tistically significant. Trend analyses were performed using the
Mantel–Haentszel chi-square test. Multivariable logistic regres-
sion was used to determine independent predictors of in-patient
mortality.
Results
Patient and hospital demographics
During the sampled time frame of 1998–2006, 4013 weighted
patient-discharges (n = 813 unweighted) were identified for
patients who underwent TP. Patient and hospital demographics of
the cohort are shown in Table 1. The mean age of patients was 58
years [95% confidence interval (CI) 57–60]. The majority of the
cohort was White (58.8%, n = 2360), followed by non-Whites
(18.1%, n = 726). Race information was missing for 23.1% (n =
927) of the cohort and race was then excluded from any further
analyses. Similar numbers of males and females underwent TP
(male 52.9%, n = 2124 vs. females 47.1% n = 1889, P = 0.14). The
majority of patients undergoing TP had comorbidities as evi-
denced by an elevated Charlson score (Charlson score 2, 20%, n =
804, Charlson score 3 45.3%, n = 1817, P < 0.01). The majority
of TPs were performed for neoplastic disease (67.8%, n = 2719),
followed by pancreatitis (19.2%, n = 770), other/unspecified pan-
creatic disease (10.6%, n = 425) and pancreatic cystic disease
(2.5%, n = 99) (P < 0.0001).
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TP was more likely to be performed in a teaching hospital
(77.1%, n = 3088) than a non-teaching hospital (22.9%, n = 916).
The majority of TPs (86.4%, n = 3467) were performed at insti-
tutions performing fewer than five pancreatic resections per year
(P < 0.0001). Nationwide utilization of TP increased significantly
over the time period studied with 384 TPs performed in 1998 and
494 performed in 2006 (P < 0.01 trend analysis) (Fig. 1).
Post-operative complications and patient disposition
Major in-hospital complications occurred in 28% (n = 1136) of
patients who underwent TP (Fig. 2). Pulmonary compromise
(12%, n = 485), gastrointestinal (GI) haemorrhage (4.2%, n = 168)
and DVT/ PE (3.7%, n = 149) were the most frequent complica-
tions (Fig. 2).
Mean LOS was 16.6 days (95% CI 15.3–17.8) for patients
undergoing TP. After TP, the majority of patients were discharged
home (56%, n = 2236) with an additional 23% (n = 939) dis-
charged home with visiting nurse services. A smaller percentage
(12%, n = 487) were discharged to either a short-term rehabilita-
tion centre or skilled nursing facility (Fig. 3).
Table 1 Patient and hospital characteristics for total pancreatectomy
including univariate analyses, Nationwide Inpatient Sample (NIS)
1998–2006
Weighted
number (%)
P-value
Total (n = 813) 4013 (100)
Age (years) <0.0001
Mean [SEM] 58.4 [0.77]
<50 1080 (26.9)
50–69 1863 (46.4)
>70 1070 (26.7)
Sex 0.14
Male 2124 (52.9)
Female 1889 (47.1)
Race <0.0001
White 2360 (58.8)
Non-White 726 (18.1)
Other 927 (23.1)
Insurance status <0.0001
Medicare 1612 (40.2)
Private/HMO 1817 (45.3)
Medicaid/self-pay 419 (10.4)
No charge/other 165 (4.1)
Teaching status <0.0001
Teaching 3088 (77.1)
Non-teaching 925 (22.9)
Hospital volume <0.0001
<five resections/year 3467 (86.4)
five resections/year 546 (13.6)
Year <0.01
98–00 1240 (30.9)
01–03 1378 (34.4)
04–06 1395 (34.7)
Charlson score <0.0001
0 894 (22.3)
1 498 (12.4)
2 804 (20.0)
 3 1817 (45.3)
Indication <0.0001
Neoplastic disease 2719 (67.8)
Pancreatitis 770 (19.1)
Cyst/benign 99 (2.5)
Other/unspecified 425 (10.6)
SEM, standard error of mean.
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Figure 1 Annual volume and in-hospital mortality for total pancre-
atectomy, Nationwide Inpatient Sample (NIS) 1998–2006
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Figure 2 Major in-hospital complications after total pancreatectomy.
MI, myocardial infraction; DVT, deep vein thrombosis; PE, pulmonary
embolism; GI, gastrointestinal; MI = Myocardial Infarction; DVT =
Deep Venous Thrombosis; PE = Pulmonary Embolism; GI =
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Univariate analyses of mortality
Over the years studied, the overall in-patient mortality rate for TP
was 8.5% as shown in Table 2. In-patient mortality significantly
decreased over time with in-patient mortality in 1998 of 14.2%
which declined to 5.7% in 2006 (trend P < 0.01) (Fig. 1).
Advanced age was associated with increased in-patient mortality
(70 years, 12.6%, n = 135, vs. 50–69 years, 8.2%, n = 153, vs. <50
years, 4.8%, n = 52, P < 0.05). Comorbidities were associated with
increased mortality risk (Charlson score 0, 6.1%, n = 55 vs. Charl-
son score3, 9.7%, n = 175, P < 0.01). Indication for TP was not
associated with an increased risk of mortality (P = 0.80).
In-patient mortality was similar for TP performed at both
teaching and non-teaching hospitals (8.3%, n = 255 vs. 9.2%, n =
85, P = 0.37). Hospital volume of pancreatic resection correlated
significantly with peri-operative mortality on univariate analyses.
Among hospitals performing fewer than five pancreatic resections
annually, in-patient mortality for TP was 9% (n = 312). In com-
parison, in-patient mortality was 5.2% (n = 28) for hospitals
performing five pancreatic resections annually (P < 0.01).
Multivariable analyses
Using a multivariable logistic regression model, independent pre-
dictors of in-hospital mortality were evaluated. Significant factors
identified on univariate analyses and those with biological plau-
sibility were incorporated into the model with results demon-
strated in Table 3. Patient characteristics including advanced age
(referent50 years;70 years, AOR 3.40, 95% CI 1.33–8.67) and
the presence congestive heart failure (CHF) (referent = no CHF;
AOR 3.39, 95% CI 1.26–9.11), liver disease (referent = no liver
disease; AOR 6.80, 95% CI 2.72–17.02) or renal failure (referent =
no renal failure; AOR 4.52; 95% CI 1.47–13.89) were indepen-
dently predictive of increased in-patient mortality. During 1998 to
2000, patients undergoing TP had a 2.7-fold increased risk (95%
CI 1.41–5.14) of peri-operative mortality when compared with
TPs performed during the more recent time period of 2004–2006.
Neither hospital teaching status nor hospital volume of pancreatic
resections was independently associated with peri-operative mor-
tality for TP on multivariate analyses.
Discussion
We performed a national review of total pancreatectomy per-
formed for neoplastic and benign indications.We found a signifi-
cant increase in the number of TPs performed annually from
1998–2006 with a concomitant decrease in peri-operative mortal-
ity. Patient characteristics including advanced age and the pres-
ence of select comorbid conditions (congestive heart failure, liver
disease and renal disease) independently predicted in-patient
mortality. Indication for TP and hospital characteristics
including annual resection volume and teaching status, were not
Home
56%
Died
9%
STR/SNF
12%
VNA
23%
Figure 3 Patient disposition after total pancreatectomy. STR, short-
term rehabilitation; SNF, skilled nursing facility; VNA, visiting nurse
Table 2 Univariate analyses of in-patient mortality for total pancre-
atectomy, Nationwide Inpatient Sample (NIS) 1998–2006
Weighted
number
Mortality
rate (%)
P-value
Total (n = 813) 340 8.5
Age (years) <0.05
<50 52 4.8
50–69 153 8.2
>70 135 12.6
Gender 0.22
Male 169 8.0
Female 171 9.1
Race 0.15
White 194 8.2
Non-White 54 7.5
Other 92 10
Insurance status <0.0001
Medicare 174 10.9
Private/HMO 108 5.9
Medicaid/self-pay/other 58 9.9
Teaching status 0.37
Teaching 255 8.3
Non-teaching 85 9.2
Hospital volume <0.01
<five resections/year 312 9.0
five resections/year 28 5.2
Year <0.01
98–00 154 12.4
01–03 103 7.6
04–06 83 5.9
Charlson score <0.01
0 55 6.1
1 51 10.4
2 59 7.4
3 or more 175 9.7
Indication 0.80
Neoplastic disease 229 8.4
Benign disease 111 8.7
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independently associated with perioperative mortality. TP was
associated with significant morbidity with major in-hospital com-
plications occurring in nearly 30% of patients.
Historically, operative mortality for TP has been high, with
single-institution rates greater than 20%.19,20 Prohibitive mortality
coupled with significant morbidity managing the apancreatic
state, led some surgeons to argue against the use of TP.21 However,
recent single-institution series have reported lower peri-operative
mortality rates for TP ranging from 3% to 6.1%.6,7,22,23 Our overall
national rate of 8.5% for peri-operative mortality is slightly
higher, although when reviewing themost recent years included in
our study (2004–2006), we found peri-operative mortality to be
5.7–6.3%. Consistent with our findings, McPhee et al. reported
decreasing perioperative mortality associated with TP in a
national review of all types of pancreatectomy performed for
neoplastic disease.18
Post-operative surgical morbidity associated with TP remains
high with complication rates ranging from 36% to 54% in single-
institution series.6,22,23 In our cohort, 28% developed a major post-
operative complication during their hospital stay. This number is
likely underestimated, as we utilized a set of validated complica-
tion codes, therefore limiting the number of complications evalu-
ated. Despite the relatively high complication rate, nearly 80% of
patients were discharged home after TP (with/without visiting
nurse services).
The call for regionalization of complex, high mortality-rate
procedures to large, high-volume centres has been well described
in the literature.24,25 We found high volume hospitals (five pan-
creatic resections/year) to be associated with improved survival
for TP on univariate analyses. However, after adjustment for addi-
tional covariates in multivariable analyses, high volume hospitals
were no longer protective against peri-operative mortality. Indi-
vidual patient factors, namely advanced age (>70 years) and the
presence of comorbid conditions, were predictive of increased
mortality. This suggests that careful patient selection may be more
prognostic for in-patient mortality than absolute hospital surgical
volume. The majority of TPs were performed at institutions per-
forming fewer than five resections per year.
While our study demonstrates the recent national trends for TP,
its limitations must be acknowledged. The NIS is an administra-
tive database and therefore lacks certain clinical information
including patient-level factors (pre-operative performance status
and laboratory values), operative data (blood loss and transfu-
sions), and long-term follow-up/re-admission information. Racial
demographic information was largely missing necessitating
removal of race from multivariable analyses. The NIS provides
information on individual hospital admissions, allowing for
evaluation of in-hospital mortality. This may reflect a lower rate
when compared with studies utilizing 30-day mortality rates. We
evaluated post-operative complications using a validated set of
ICD-9 codes,17 however, the true complication rate may have been
underestimated. Long-term outcomes of managing the post-
operative apancreatic state were not available for evaluation.
However, despite these limitations, the NIS provides a mechanism
to study national trends of procedures, diagnoses and outcomes
including in-patient mortality.
Indications for TP are being re-visited as the peri-operative
mortality rate has becomemore acceptable. Concern regarding the
extent of ductal disease for IPMN has led to the inclusion of TP in
the armamentariumof surgical options.9,26,27 Intractable pain asso-
ciated with chronic pancreatitis refractory to medical manage-
ment, has been shown to significantly improve after TP.10,28,29
Additionally, TP may serve a role in diseases likely affecting the
entire gland including familial pancreatic adenocarcinoma, neu-
roendocrine tumours,26 and metastatic disease.11 Management of
the diabetic state afterTPhas been improvedwith the availability of
long-acting insulin and continuous subcutaneous insulin pumps.30
Table 3 Logistic regression of in-hospital mortality for total pancre-
atectomy, Nationwide Inpatient Sample (NIS) 1998–2006
AOR 95% CI
Patient gender
Male Referent
Female 1.09 0.65–1.82
Age groups (years)
<50 Referent
50–69 2.25 0.93–5.43
70 3.40 1.33–8.67
Year group
1998–2000 2.70 1.41–5.14
2001–2003 1.67 0.82–3.38
2004–2006 Referent
Comorbidities Referent = none
Diabetes 0.60 0.29–1.06
Chronic lung disease 0.82 0.35–1.95
Congestive heart failure 3.39 1.26–9.11
Valvular heart disease 2.02 0.47–8.79
Liver disease 6.80 2.72–17.02
Renal failure 4.52 1.47–13.89
Obesity 0.71 0.08–6.67
Hospital volume
<five resections/year 1.96 0.54–7.11
five resections/year Referent
Teaching status
Teaching Referent
Non-teaching 0.85 0.46–1.56
Indication
Neoplastic disease Referent
Pancreatitis 1.50 0.70–3.24
Cyst/benign 0.92 0.17–5.00
Other/unspecified 1.36 0.46–3.99
AOR, adjusted odds ratio; CI, confidence interval.
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Pancreatic enzyme replacement has assisted in the treatment of the
acquired exocrine deficiency after TP.
With expanding indications and improved post-operative
treatment strategies, TP is increasingly performed nationwide.
While in-hospital morbidity remains substantial, TP is a viable
option for specific indications with acceptable in-patient mortal-
ity. Careful patient selection and pre-operative counselling may
further improve patient outcomes for TP. Additional studies
including patient-level data, operative information, quality of life
and long-term survival are warranted to provide a fuller under-
standing of the specific predictors of outcome after TP.
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Appendix 1
ICD-9-CM diagnoses
Indication
Neoplastic disease 157.1, 157.2, 157.3, 157.0, 157.4, 157.8, 157.9, 156.2, 156.1, 152.0, 197.8, 151.8, 196.2,
197.4, 197.6, 153.7, 194.0, 156, 156.0, 156.8, 230.9, 235.5, 239.0, 211.6, 235.3, 211.5, 230,
230.2, 230.7, 230.8, 230.9, 235.2, 235.3, 235.4, 235.5, 239.9, 211, 211.1, 211.2, 211.6,
211.7, 211.8, 211.9, 239, 239.8, 239.9, 158.0, 189.0, 202.82, 151.4, 153.3, 159.9
Pancreatitis 577.0, 577.1, 576.1
Cystic disease 577.2
Complications
Post-operative infection 000.45, 320.00–320.99, 510.0, 510.9, 513.1, 519.2, 590.10–590.11, 590.80, 683
Myocardial infarction 410.00–410.91
Aspiration pneumonia 507.0
Deep venous thrombosis/pulmonary embolism 415.1, 451.11, 451.19, 451.2, 451.81, 453.8
Pulmonary compromise 514, 518.4, 518.5, 518.81, 518.82
Gastrointestinal haemorrhage 530.82, 531.00–531.21, 531.40–531.41, 531.60–531.61, 532.00–532.21, 532.40–532.41,
533.60–533.61, 534.00–534.21, 534.40–534.41, 534.60–534.61, 535.01, 535.11, 535.21,
535.31, 353.41, 535.51, 535.61, 578.9
Reopening surgical site 01.23, 03.03, 06.02, 34.09, 35.95, 39.49, 54.12, 54.61
Procedure-related perforation or laceration 530.4, 569.83, 575.4, 29.51, 31.61, 33.41, 33.43, 42.82, 44.61, 46.71, 46.75, 48.71, 50.61,
51.91, 55.81, 56.82, 57.81, 58.41, 69.41
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